Form DEFA14A Werewolf Therapeutics,
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)
|
Filed by the Registrant ☒
|
|
|
Filed by a Party other than the Registrant ☐
|
Check the appropriate box:
|
☐
|
|
|
Preliminary Proxy Statement
|
|
☐
|
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
|
|
Definitive Proxy Statement
|
|
☒
|
|
|
Definitive Additional Materials
|
|
☐
|
|
|
Soliciting Material under §240.14a-12
|
WEREWOLF THERAPEUTICS, INC.
(Name of registrant as specified in its charter)
(Name of person(s) filing proxy statement, if other than the registrant)
Payment of Filing Fee (Check the appropriate box):
|
☒
|
|
|
No fee required
|
|
☐
|
|
|
Fee paid previously with preliminary materials
|
|
☐
|
|
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 11 06 2026] - (CGWL)
- Dofo Tea Refreshes Its Look to Make a Centuries-Old Tea Ritual Feel at Home in Any Kitchen
- CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
